Ismael Buno
Overview
Explore the profile of Ismael Buno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
644
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pena-Burgos E, Serra Del Carpio G, Tapia-Vine M, Suarez-Gonzalez J, Buno I, Ortiz-Cruz E, et al.
Diagnostics (Basel)
. 2025 Mar;
15(5).
PMID: 40075784
: Liposclerosing myxofibrous tumors (LSMFTs) have been described as an infrequent and peculiar fibrous dysplasia variant with a predilection for the intertrochanteric femoral region and are not globally considered a...
2.
Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland J, Brieghel C, et al.
Hemasphere
. 2025 Jan;
9(1):e70065.
PMID: 39840379
In chronic lymphocytic leukemia, the reliability of next-generation sequencing (NGS) to detect variants ≤10% allelic frequency (low-VAF) is debated. We tested the ability to detect 23 such variants in 41...
3.
de la Iglesia-San Sebastian I, Lopez-Esteban M, Bastos-Oreiro M, Fernandez de Cordoba-Onate S, Gutierrez M, Carbonell D, et al.
Br J Haematol
. 2024 Dec;
206(1):195-203.
PMID: 39668521
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for aggressive B-cell lymphomas (ABCL), However, about half of patients relapse, most of them early. This study investigates...
4.
Diaz M, Vazquez-Gomez F, Garrido I, Arias F, Suarez J, Buno I, et al.
Curr Oncol
. 2024 Nov;
31(11):7308-7318.
PMID: 39590169
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median overall survival (OS) of 15-18 months despite standard treatments. Approximately 8% of GBM cases exhibit...
5.
Muniz P, Martinez-Garcia M, Bailen R, Chicano M, Oarbeascoa G, Trivino J, et al.
Front Immunol
. 2024 Sep;
15:1396284.
PMID: 39247183
Backgrounds: Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for hematological malignancies, it can be associated with relevant post-transplant complications. Several reports have shown that polymorphisms...
6.
de la Iglesia-San Sebastian I, Carbonell D, Bastos-Oreiro M, Perez-Corral A, Bailen R, Chicano M, et al.
Transplant Cell Ther
. 2024 Jan;
30(3):306.e1-306.e12.
PMID: 38184148
Chimeric antigen receptor T cells (CAR-T) has emerged as a promising therapy, over 60% of patients fail to sustain a long-term response. The underlying factors that leads to the effectiveness...
7.
Rodriguez-Macias G, Briz O, Cives-Losada C, Chillon M, Martinez-Laperche C, Martinez-Arranz I, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370755
Despite its often low efficacy and high toxicity, the standard treatment for acute myeloid leukemia (AML) is induction chemotherapy with cytarabine and idarubicin. Here, we have investigated the role of...
8.
Gomez-Centurion I, Rojas R, Bailen R, Munoz C, Sabell S, Oarbeascoa G, et al.
Ann Hematol
. 2023 Apr;
102(6):1561-1567.
PMID: 37083956
This is a retrospective cohort study of consecutive adult patients who received a haploidentical-SCT (haplo-SCT) with post-transplant cyclophosphamide (PT-Cy) in a single centre. Poor graft function (PGF) was defined as...
9.
Bastos-Oreiro M, Sanz-Villanueva L, Muniz P, Bailen R, Chicano M, Oarbeskoa G, et al.
Transplant Cell Ther
. 2023 Mar;
29(7):472.e1-472.e4.
PMID: 36921917
We propose a novel biomarker that can identify patients at high risk of early progression after chimeric antigen receptor (CAR) T cell therapy. Calculation of cell-free DNA (cfDNA) with a...
10.
Andres-Zayas C, Suarez-Gonzalez J, Chicano-Lavilla M, Oreiro M, Rodriguez-Macias G, Font Lopez P, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765901
The familial occurrence of hematological malignancies has been underappreciated. Recent studies suggest that up to 15% of adults with myeloid neoplasms carry germline pathogenic variants in cancer-predisposing genes. This study...